Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.939,32
0,83%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Axonics Inc (AXNX) Axonics Inc (AXNX) Notizie

Axonics Inc

AXNX
66,69
0,15 (0,23%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
24/4/202412:30PRNUSBoston Scientific Announces Results for First Quarter 2024
22/3/202421:01BWAxonics Stockholders Approve Merger Agreement with Boston..
21/3/202421:54BWAxonics Provides Update on Inter Partes Review Proceedings
14/3/202411:00BWAxonics Receives CE Mark Approval for Fourth-Generation..
07/3/202423:24EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/2/202422:01BWAxonics Responds to ITC Action by Medtronic
28/2/202422:05EDGAR2Form 8-K - Current report
28/2/202422:01BWAxonics Reports Fourth Quarter and Fiscal Year 2023..
22/2/202414:00EDGAR2Form DEFM14A - Definitive proxy statement relating to merger..
03/2/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202423:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202423:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202423:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202412:30PRNUSBoston Scientific Announces Results for Fourth Quarter and..
11/1/202402:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202421:07PRNUSKuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to..
08/1/202423:19EDGAR2Form DEF 14A - Other definitive proxy statements
08/1/202423:19EDGAR2Form 8-K - Current report
08/1/202422:55PRNUSALERT: Rowley Law PLLC is Investigating Proposed Acquisition..
08/1/202417:36DJNAxonics Shares Climb 20% After Acquisition by Boston..
08/1/202414:47EDGAR2Form 8-K - Current report
08/1/202413:41DJNBoston Scientific To Acquire Axonics For About $3.7 Billion
08/1/202413:00BWAxonics Announces Definitive Agreement to be Acquired by..
29/12/202301:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202322:01BWAxonics to Present at the J.P. Morgan Healthcare Conference
26/12/202319:31EDGAR2Form 144 - Report of proposed sale of securities
06/11/202318:00GLOBERevolutionizing Care: NeuroQure’s Groundbreaking Path to..
01/11/202311:00BWAxonics to Participate in November Investor Conferences
30/10/202321:06EDGAR2Form 8-K - Current report
30/10/202321:01BWAxonics Reports Third Quarter 2023 Financial Results
07/10/202302:04EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/10/202322:08EDGAR2Form 8-K - Current report
04/10/202301:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202312:00BWAxonics to Report Third Quarter 2023 Financial Results on..
25/8/202312:00BWAxonics to Participate in September Investor Conferences
21/8/202323:59EDGAR2Form 144 - Report of proposed sale of securities
21/8/202323:30EDGAR2Form 8-K - Current report
21/8/202312:00BWAxonics Announces CFO Retirement and Appoints Successor
31/7/202323:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
27/7/202322:05EDGAR2Form 8-K - Current report
27/7/202322:01BWAxonics Reports Second Quarter 2023 Financial Results
29/6/202312:00BWAxonics to Report Second Quarter 2023 Financial Results on..
29/6/202302:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202302:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/5/202322:01BWAxonics Reports First Quarter 2023 Financial Results
Apertura: 66,75 Min: 66,50 Max: 66,875
Chiusura: 66,54

La tua Cronologia

NASDAQ
AXNX
Axonics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network